Jan 10, 2022 / 01:15PM GMT
David James Adlington - JPMorgan Chase & Co, Research Division - Head of Medical Technology and Services Equity Research
Good morning, good afternoon, everybody. I'm David Adlington. I head up the JPMorgan med tech team in Europe. It's my pleasure this morning to introduce Stephan Sturm and Markus Georgi, CEO and Investor Relations for Fresenius SE. Presentation is slightly shorter than most speakers, so 10 to 15 minutes, and then we'll open it up to Q&A. (Operator Instructions) With that, Stephan, thanks for joining us today, and over to you.
Stephan Sturm - Fresenius SE & Co. KGaA - CEO, President & Chairman of Management Board - Fresenius Management SE
Thank you, David. Good morning, good afternoon, everyone. Happy new year. Thank you for joining. Your interest in Fresenius is much appreciated as always. The COVID pandemic has been and remains a net burden for us as a group, maybe counterintuitively, maybe surprisingly, that is why I am keen to pointing it out. Important words here are our excess mortality among dialysis patients at medical
Fresenius SE & Co KGaA at JPMorgan Healthcare Conference (Virtual) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot